<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of the study was to determine in human malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> the expression patterns of <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> phosphoribosyltransferase (NAMPT) and <z:chebi fb="5" ids="15940">nicotinic acid</z:chebi> phosphoribosyltransferase (NAPRT), the primary, rate-limiting enzymes in the synthesis of <z:chebi fb="0" ids="13389">NAD</z:chebi>+ </plain></SENT>
<SENT sid="1" pm="."><plain>NAMPT is a potential biomarker for sensitivity to NAMPT inhibitors and NAPRT is a biomarker for the use of <z:chebi fb="5" ids="15940">nicotinic acid</z:chebi> as a chemoprotectant in treatment with NAMPT inhibitors </plain></SENT>
<SENT sid="2" pm="."><plain>The NAMPT inhibitor, APO866, is currently in clinical phase II trials in <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The expression of NAMPT and NAPRT was investigated in 53 samples of malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="4" pm="."><plain>The expression of NAMPT was generally high in the more aggressive malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, with &gt;80% strong expression, whereas the expression in the more indolent follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) was significantly lower (&gt;75% moderate or low expression, p = 0.0002) </plain></SENT>
<SENT sid="5" pm="."><plain>NAMPT was very highly expressed in Hodgkin Reed-Sternberg cells in Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>NAPRT expression was more varied (p &gt; 0.0001) with 30-50% low expression except for Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> where 85% displayed low expression (p = 0.0024) </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, FL are a promising target for NAMPT inhibitors whereas substantial subsets of malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> especially in Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> may be suitable for a combination treatment with <z:chebi fb="5" ids="15940">nicotinic acid</z:chebi> and NAMPT inhibitors </plain></SENT>
</text></document>